Key Takeaways Gilead Sciences' 2025 HIV sales rose 6%, beating its 5% target despite a $900M Medicare headwind.Biktarvy held 52% share, while Descovy sales jumped 31% to $2.8B on strong demand and pricing.Yeztugo generated $150M in 2025; Gilead Sciences sees HIV sales up 6% in 2026.Gilead Sciences, Inc. (GILD) has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy for treatment and Descovy for prevention.Earlier this week, the company reported strong fourth-quarter and full-year 2025 r ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical research stocks to buy according to hedge funds. On February 11, BofA lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $162 from $154, maintaining a Buy rating on the shares. The firm told investors in a post-earnings note that it is confident in 2026 growth for the company due to solid fiscal Q4 dynamics, adding that it no longer models Yeztugo cannibalization of Descovy sales in 2026. Gilead (GILD) Reaches Pricing Agreement ...

Economic Overview - The U.S. economic landscape remains resilient with major indexes moving higher, driven by strong earnings from large technology companies and steady consumer spending [1] - The Dow Jones Industrial Average closed above the 50,000 mark for the first time in February 2026 [1] - Market participants expect the Federal Reserve to begin cutting interest rates later this year, although there is uncertainty regarding new Fed leadership and future monetary policy [1] Inflation and Geopolitical Concerns - Inflation is currently above the Fed's long-term target of 2%, which may lead the central bank to maintain higher interest rates for an extended period [2] - Rising geopolitical tensions pose a significant concern, potentially impacting U.S. exports and corporate profits [2] Investment Trends - Investors are shifting towards steady industrial growth stocks due to concerns over high valuations in technology companies and the costs associated with sustaining the AI revolution [3] - Economic reports are being closely monitored, as even minor surprises could lead to significant market movements [3] Dividend-Paying Stocks - In the current market conditions, investors looking to diversify can consider dividend-paying stocks, which indicate a healthy business model [4] - Stocks that have recently increased dividends tend to exhibit a sound financial structure and can withstand market volatility [4] Company Highlights NetEase (NTES) - NetEase is an Internet technology company based in China, with a dividend of $1.16 per share declared for March 27, 2026, and a dividend yield of 1.9% [5] - Over the past five years, NTES has increased its dividend 10 times, with a payout ratio of 29% of earnings [6] Penske Automotive Group (PAG) - Penske Automotive Group operates automotive and commercial truck dealerships globally, declaring a dividend of $1.40 per share for March 5, 2026, with a dividend yield of 3.2% [7] - PAG has increased its dividend 20 times in the past five years, with a payout ratio of 38% of earnings [8] Urban Edge Properties (UE) - Urban Edge Properties is a real estate investment trust focused on shopping centers, declaring a dividend of 21 cents per share for March 31, 2026, with a dividend yield of 3.7% [9][11] - UE has increased its dividend five times over the past five years, with a payout ratio of 54% of earnings [11] Gilead Sciences (GILD) - Gilead Sciences specializes in developing drugs for HIV treatment, declaring a dividend of 82 cents per share for March 30, 2026, with a dividend yield of 2% [12] - GILD has increased its dividend six times in the past five years, with a payout ratio of 39% of earnings [12] Royal Caribbean Cruises (RCL) - Royal Caribbean Cruises operates multiple global cruise brands, declaring a dividend of $1.50 per share for April 3, 2026, with a dividend yield of 1.2% [13] - RCL has increased its dividend five times over the past five years, with a payout ratio of 26% of earnings [14]

今日上午港股 1 . 津上机床中国(01651)涨近6%，再创历史新高。截至发稿，涨4.97% 。消息面上，津上机床中国近 日公布，控股股东日本津上截至2025年12月31日止9个月的财务业绩，在中国，收入为815.8亿日圆， 同比增加28.3%；分部溢利为225.34亿日圆，同比增加51.2%。 2 . 智谱(02513)涨幅扩大逾26%，截至发稿，涨25.8% 。消息面上，2月11日，智谱正式发布新一代旗 舰模型GLM-5。在Coding与Agent能力上，GLM-5取得开源SOTA表现，在真实编程场景的使用体感逼 近Claude Opus4.5，擅长复杂系统工程与长程Agent任务。 3 . 中核国际(02302)再涨超7%，截至发稿，涨6.7% 。消息面上，中核国际近期公布公告称，预期2025 年度收入将不少于24.6亿港元，毛利将不少于2.6亿港元，较2024年同期实现稳步提升。公司收入增长 的核心动力明确来自铀贸易业务交易量的提升。 4. 天域半导体(02658)盘中涨近8%，截至发稿，涨5.18% 。消息面上，近日，天域半导体宣布与韩国 第三代半导体领军企业EYEQ Lab Inc.正式签署战略 ...

Biotech leader Gilead Sciences (GILD)  made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results yesterday evening.Thanks to its durable drug pipeline for HIV and liver disease, Gilead's stock has been on a captivating ascension in the last two years, producing gains of +100% and hitting an all-time high of $157 a share in today’s trading session. Gilead’s Favorable Q4 resultsGilead posted Q4 sales of $7.92 billion, a 5% increase from $7.56 billion in the comparativ ...

Core Viewpoint - Gilead Sciences is experiencing strong financial performance and growth potential, particularly in its HIV and liver disease segments, supported by a robust pipeline of new products and an optimistic outlook from analysts [1][2][3][4][6]. Financial Performance - Gilead's Q4 2025 earnings report showed total product sales of $7.9 billion, marking a 5% increase year-over-year [2][6]. - For the full year 2025, total sales reached $28.9 billion, reflecting a 1% increase from 2024 [2][6]. - HIV sales specifically grew by 6% year-over-year, driven by the success of the drug Biktarvy and a 47% increase in the HIV prevention portfolio [2][6]. Product Developments - The new HIV prevention injectable, Yeztugo, has surpassed coverage goals and is gaining market share [3][6]. - Gilead's pipeline includes up to 10 ongoing and potential new launches through 2027, with four commercial launches planned for 2026 [3][6]. - The liver business reported a 6% growth, attributed to the adoption of Livdelzi for primary biliary cholangitis [4][6]. - Trodelvy, an oncology product, also demonstrated positive momentum with a 6% growth in 2025, supported by favorable Phase results [4][6]. Analyst Ratings - BMO Capital has maintained an "Outperform" rating for Gilead, raising the price target from $150 to $160, indicating confidence in the company's future performance [1][6].

Core Viewpoint - Gilead Sciences, Inc. reported strong fourth-quarter results for 2025, with adjusted earnings per share (EPS) of $1.86, exceeding estimates, while total revenues of $7.9 billion also surpassed expectations, driven by growth in HIV and Liver Disease drugs [1][4][6]. Financial Performance - Adjusted EPS for Q4 2025 was $1.86, beating the Zacks Consensus Estimate of $1.83, but down from $1.90 a year ago due to higher acquired IPR&D expenses [1][6]. - Total revenues reached $7.9 billion, a 5% increase year over year, surpassing the Zacks Consensus Estimate of $7.6 billion [1][4]. - Product sales increased by 5% year over year to $7.9 billion, with HIV product sales growing 6% to $5.8 billion [4][5]. Product Sales Breakdown - Biktarvy sales rose 5% year over year to $4 billion, capturing over 52% of the U.S. HIV treatment market [5][6]. - Descovy sales surged 33% year over year to $819 million, driven by increased demand for HIV prevention [6][7]. - Liver Disease portfolio sales increased 17% to $844 million, exceeding estimates, primarily due to demand for Livdelzi [8]. - Veklury sales fell 37% to $212 million, attributed to lower COVID-19 hospitalization rates [8]. Cost and Expenses - Adjusted product gross margin was 86.8%, slightly up from 86.7% year over year [11]. - Research and development expenses remained flat at $1.6 billion, while SG&A expenses decreased to $1.7 billion from $1.9 billion [11][12]. 2025 and 2026 Guidance - For 2025, revenues rose 2% year over year to $29.4 billion, exceeding estimates, with adjusted EPS increasing to $8.15 from $4.62 in 2024 [13]. - Gilead expects 2026 product sales between $29.6 billion and $30 billion, with adjusted EPS projected in the range of $8.45-$8.85 [14][15]. Pipeline and Regulatory Updates - Positive phase III results for the investigational regimen of bictegravir and lenacapavir were reported, with a potential launch targeted for the second half of the year [16][23]. - Gilead has discontinued several studies based on recommendations from independent committees, including the phase III STAR-221 study [18][19]. Market Position and Competitive Landscape - Gilead's HIV business exceeded management's growth target, driven by strong performances from Biktarvy and Descovy, despite competitive pressures [21][22]. - The company anticipates continued competitive pressures in cell therapies and expects to face headwinds from U.S. government drug pricing agreements [24][27].

周三，吉利德科学(GILD.US)涨逾5%，报155.54美元，股价再创历史新高。吉利德科学最新公布的财报 显示，2025年全年公司营业收入达294.43亿美元，同比增长2.4%；归属上市公司净利润85.1亿美元，同 比大幅增长约16.73倍，非公认会计原则(Non-GAAP)稀释后每股收益8.15美元，同比大幅增长77%。 吉利德董事长兼首席执行官丹尼尔奥戴介绍，去年是公司成果丰硕的一年，全球首款半年一次HIV预防 疗法Yeztugo成功上市，必妥维(Biktarvy)与Descovy持续增长，为公司奠定了坚实的增长基础。 ...

格隆汇2月11日｜吉利德科学(GILD.US)涨5.8%，最高触及155.75美元，创下历史新高。消息面上，吉利 德科学公布去年第四季度业绩，营收同比增长5%至79亿美元，超过分析师预期的77亿美元；调整后每 股收益为1.86美元，亦超过预期的1.81美元。期内，艾滋病相关产品销售额同比增长6%至58亿美元，主 要受艾滋病预防和治疗需求增加推动。(格隆汇) ...

Gilead Sciences Inc. (NASDAQ:GILD) posted upbeat fourth-quarter earnings but issued weak fiscal 2026 guidance on Tuesday.Gilead reported quarterly earnings of $1.86 per share, which beat the consensus estimate of $1.81, according to data from Benzinga Pro. Quarterly revenue came in at $7.93 billion, which beat the Street estimate of $7.69 billion."Our fourth quarter and full-year results close out a very strong year for Gilead overall, including the successful U.S. launch of Yeztugo, the world's first twice ...